Biogen Inc. buy Royal Bank of Canada
Start price
12.02.24
/
50%
€226.20
Target price
12.02.25
€351.83
Performance (%)
-43.30%
End price
13.02.25
€128.25
Summary
This prediction ended on 13.02.25 with a price of €128.25. The BUY prediction by Royal_Bank_of_Canada for Biogen Inc. performed very badly with a performance of -43.30%. Royal_Bank_of_Canada has a follow-up prediction for Biogen Inc. where he still thinks Biogen Inc. is a Buy. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Biogen Inc. | 3.296% | 3.296% | 50.228% |
| iShares Core DAX® | 1,60 % | 5,04 % | 3,87 % |
| iShares Nasdaq 100 | 3,74 % | 14,95 % | 36,14 % |
| iShares Nikkei 225® | 3,74 % | 13,89 % | 43,81 % |
| iShares S&P 500 | 1,82 % | 8,88 % | 25,51 % |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biogen Inc. diskutieren
Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Royal Bank of Canada from $363.00 to $379.00. They now have an "overweight" rating on the stock.
Ratings data for BIIB provided by MarketBeat
In the thread Trading Biogen Inc.
Die von Royal_Bank_of_Canada gewählte maximale Laufzeit wurde überschritten